Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease

Gut. 2005 Feb;54(2):314-5; author reply 316-6.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / pharmacology*
  • Crohn Disease / drug therapy*
  • Etanercept
  • Humans
  • Immunity, Mucosal / drug effects
  • Immunoglobulin G / pharmacology*
  • Infliximab
  • Intestinal Mucosa / immunology
  • Receptors, Tumor Necrosis Factor
  • Signal Transduction / drug effects
  • T-Lymphocyte Subsets / drug effects*

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Infliximab
  • Etanercept